It is now appreciated in the ovarian cancer literature that upon treatment with standard platinum-based chemotherapy, BRCA1- and BRCA2-associated malignancies have an improved prognosis compared to sporadic epithelial ovarian cancers [44]. The gene discussed is BRCA2; the disease is ovarian cancer.